|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Kaplan-Meier analysis indicated that patients presenting with reduced ITM2A expression exhibited poor overall survival, and expression significantly correlated with age, progesterone receptor status, TNM classification and tumor stage.
|
31438969 |
2019 |
|
Graves Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Moreover, ITM2A expression was significantly decreased in PBMCs from untreated GD patients than that from controls.
|
27809695 |
2017 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
ITM2A loss occurred in 45.6% (41 of 90) of invasive carcinomas and was significantly associated with FIGO stage, type II tumors, suboptimal debulking operation, recurrence and chemoresistance.
|
26691219 |
2016 |
|
Graves Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In this study, we carried out a three-stage study in 9529 patients with GD and 9984 controls to identify new risk loci for GD and found genome-wide significant associations in the overall populations for five novel susceptibility loci: the GPR174-ITM2A at Xq21.1, C1QTNF6-RAC2 at 22q12.3-13.1, SLAMF6 at 1q23.2, ABO at 9q34.2 and an intergenic region harboring two non-coding RNAs at 14q32.2 and one previous indefinite locus, TG at 8q24.22 (Pcombined < 5 × 10(-8)).
|
23612905 |
2013 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
MTT assay, EdU incorporation assay and colony formation assay were used to evaluated the role of ITM2A on breast cancer cell proliferation.
|
31438969 |
2019 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MTT assay, EdU incorporation assay and colony formation assay were used to evaluated the role of ITM2A on breast cancer cell proliferation.
|
31438969 |
2019 |
|
Mammary Tumorigenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Moreover, we found that ITM2A was phosphorylated at T35 by HUNK, a serine/threonine kinase significantly correlated with human breast cancer overall survival and HER2-induced mammary tumorigenesis.
|
31438969 |
2019 |
|
Bacterial Infections
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The results suggest that ITM2A might be a susceptibility gene for GD in the Xq21.1 locus, and environmental factors, such as viral and bacterial infections, probably contribute to GD pathogenesis by interacting with the risk SNP rs3827440 mediating the regulation of ITM2A expression.
|
27809695 |
2017 |
|
Familial Partial Lipodystrophy, Type 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
This suggests that targeting of Itm2a or its related pathways, including autophagy, may have potential as a therapy for FPLD2.
|
28872940 |
2017 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
ITM2A loss occurred in 45.6% (41 of 90) of invasive carcinomas and was significantly associated with FIGO stage, type II tumors, suboptimal debulking operation, recurrence and chemoresistance.
|
26691219 |
2016 |
|
Epithelial ovarian cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
|
26691219 |
2016 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
ITM2A is a new biomarker of poor prognosis in ovarian cancer.
|
26691219 |
2016 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
ITM2A is a new biomarker of poor prognosis in ovarian cancer.
|
26691219 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
ITM2A is a new biomarker of poor prognosis in ovarian cancer.
|
26691219 |
2016 |
|
Cleft Palate
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This maternally inherited 5.8 Mb rearrangement encompasses 14 genes, including BRWD3 (involved in X-linked intellectual disability), TBX22 (a gene whose alterations have been related to the presence of cleft palate), POU3F4 (mutated in X-linked deafness) and ITM2A (a gene involved in cartilage development).
|
26323392 |
2015 |
|
Cleft palate, isolated
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This maternally inherited 5.8 Mb rearrangement encompasses 14 genes, including BRWD3 (involved in X-linked intellectual disability), TBX22 (a gene whose alterations have been related to the presence of cleft palate), POU3F4 (mutated in X-linked deafness) and ITM2A (a gene involved in cartilage development).
|
26323392 |
2015 |
|
Uranostaphyloschisis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This maternally inherited 5.8 Mb rearrangement encompasses 14 genes, including BRWD3 (involved in X-linked intellectual disability), TBX22 (a gene whose alterations have been related to the presence of cleft palate), POU3F4 (mutated in X-linked deafness) and ITM2A (a gene involved in cartilage development).
|
26323392 |
2015 |
|
Intellectual Disability
|
0.010 |
GeneticVariation
|
group |
BEFREE |
This maternally inherited 5.8 Mb rearrangement encompasses 14 genes, including BRWD3 (involved in X-linked intellectual disability), TBX22 (a gene whose alterations have been related to the presence of cleft palate), POU3F4 (mutated in X-linked deafness) and ITM2A (a gene involved in cartilage development).
|
26323392 |
2015 |
|
Degenerative polyarthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Among newly identified candidate molecules, H19, IGF2, and ITM2A were significantly elevated in OA compared to normal cartilage.
|
22527881 |
2012 |